Invasive  	Invasive  	 JJ	B-NP
mycoses 	mycoses 	 NN	I-NP
:  	:  	 :	O
strategies  	strategies  	 NNS	O
for  	for  	 IN	O
effective  	effective  	 JJ	O
management  	management  	 NN	O
Effective  	Effective  	 NNP	B-NP
management  	management  	 NN	I-NP
of  	of  	 IN	I-NP
invasive  	invasive  	 JJ	I-NP
fungal  	fungal  	 JJ	I-NP
infections  	infections  	 NNS	I-NP
( 	( 	 -LRB-	O
IFIs 	IFIs 	 NNP	B-NP
)  	)  	 -RRB-	O
depends  	depends  	 VBZ	O
on  	on  	 IN	O
early  	early  	 JJ	O
individualized  	individualized  	 JJ	O
therapy  	therapy  	 NN	O
that  	that  	 IN	O
optimizes  	optimizes  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
and  	and  	 CC	O
safety 	safety 	 NN	O
.  	.  	 .	O
Considering  	Considering  	 VBG	O
the  	the  	 DT	O
negative  	negative  	 JJ	B-NP
consequences  	consequences  	 NNS	I-NP
of  	of  	 IN	I-NP
IFI 	IFI 	 NNP	I-NP
,  	,  	 ,	O
for  	for  	 IN	O
some  	some  	 DT	O
high-risk  	high-risk  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
benefits  	benefits  	 NNS	I-NP
of  	of  	 IN	I-NP
prophylactic  	prophylactic  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
may  	may  	 MD	O
outweigh  	outweigh  	 VB	O
the  	the  	 DT	O
risks 	risks 	 NNS	O
.  	.  	 .	O
When  	When  	 WRB	O
using  	using  	 VBG	O
a  	a  	 DT	O
prophylactic 	prophylactic 	 NN	O
,  	,  	 ,	O
empiric 	empiric 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
preemptive  	preemptive  	 JJ	B-NP
therapeutic  	therapeutic  	 JJ	I-NP
approach 	approach 	 NN	I-NP
,  	,  	 ,	O
clinicians  	clinicians  	 NNS	B-NP
must  	must  	 MD	O
take  	take  	 VB	O
into  	into  	 IN	O
account  	account  	 NN	O
the  	the  	 DT	O
local  	local  	 JJ	O
epidemiology 	epidemiology 	 NN	O
,  	,  	 ,	O
spectrum  	spectrum  	 NN	B-NP
of  	of  	 IN	O
activity 	activity 	 NN	O
,  	,  	 ,	O
pharmacokinetic  	pharmacokinetic  	 NN	B-NP
and  	and  	 CC	O
pharmacodynamic  	pharmacodynamic  	 JJ	B-NP
parameters 	parameters 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
of  	of  	 IN	O
different  	different  	 JJ	O
antifungal  	antifungal  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
,  	,  	 ,	O
together  	together  	 RB	O
with  	with  	 IN	O
unique  	unique  	 JJ	O
host-related  	host-related  	 JJ	O
factors  	factors  	 NNS	O
that  	that  	 WDT	O
may  	may  	 MD	O
affect  	affect  	 VB	O
antifungal  	antifungal  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
or  	or  	 CC	O
safety 	safety 	 NN	O
.  	.  	 .	O
Therapeutic  	Therapeutic  	 JJ	B-NP
drug  	drug  	 NN	I-NP
monitoring  	monitoring  	 NN	I-NP
is  	is  	 VBZ	O
increasingly  	increasingly  	 RB	O
recognized  	recognized  	 VBN	O
as  	as  	 IN	O
important  	important  	 JJ	O
or  	or  	 CC	O
necessary  	necessary  	 JJ	O
when  	when  	 WRB	O
employing  	employing  	 VBG	O
lipophilic  	lipophilic  	 JJ	B-NP
triazoles  	triazoles  	 NNS	I-NP
( 	( 	 -LRB-	O
itraconazole 	itraconazole 	 UH	B-NP
,  	,  	 ,	O
voriconazole 	voriconazole 	 NN	B-NP
,  	,  	 ,	O
posaconazole 	posaconazole 	 CD	B-NP
)  	)  	 -RRB-	O
or  	or  	 CC	O
flucytosine 	flucytosine 	 NN	B-NP
.  	.  	 .	O
Because  	Because  	 IN	O
early  	early  	 JJ	O
diagnostics  	diagnostics  	 NNS	O
remain  	remain  	 VBP	O
limited  	limited  	 VBN	O
for  	for  	 IN	O
uncommon 	uncommon 	 JJ	O
,  	,  	 ,	O
yet  	yet  	 RB	O
emerging  	emerging  	 VBG	O
opportunistic  	opportunistic  	 JJ	B-NP
molds  	molds  	 NNS	I-NP
( 	( 	 -LRB-	O
e.g. 	e.g. 	 NNP	O
,  	,  	 ,	O
Mucorales 	Mucorales 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
treatment  	treatment  	 NN	B-NP
delay  	delay  	 NN	I-NP
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
increased  	increased  	 JJ	O
mortality 	mortality 	 NN	O
,  	,  	 ,	O
early  	early  	 RB	O
effective  	effective  	 JJ	O
management  	management  	 NN	O
often  	often  	 RB	O
depends  	depends  	 VBZ	O
on  	on  	 IN	O
a  	a  	 DT	O
high  	high  	 JJ	O
index  	index  	 NN	O
of  	of  	 IN	O
suspicion 	suspicion 	 NN	O
,  	,  	 ,	O
taking  	taking  	 VBG	O
into  	into  	 IN	O
account  	account  	 NN	B-NP
predisposing  	predisposing  	 NN	I-NP
factors 	factors 	 NNS	I-NP
,  	,  	 ,	O
host  	host  	 FW	B-NP
cues  	cues  	 FW	I-NP
favoring  	favoring  	 FW	I-NP
mucormycosis 	mucormycosis 	 FW	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
local  	local  	 JJ	O
epidemiology 	epidemiology 	 NN	O
.  	.  	 .	O
Antifungal  	Antifungal  	 JJ	B-NP
options  	options  	 NNS	I-NP
for  	for  	 IN	I-NP
mucormycosis  	mucormycosis  	 NNS	I-NP
are  	are  	 VBP	O
limited 	limited 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
optimal  	optimal  	 JJ	B-NP
management  	management  	 NN	I-NP
depends  	depends  	 VBZ	O
on  	on  	 IN	O
a  	a  	 DT	O
multimodal  	multimodal  	 JJ	B-NP
approach  	approach  	 NN	I-NP
that  	that  	 WDT	O
includes  	includes  	 VBZ	O
early  	early  	 JJ	O
diagnosis 	diagnosis 	 NN	B-NP
/ 	/ 	 CD	I-NP
clinical  	clinical  	 JJ	I-NP
suspicion 	suspicion 	 NN	I-NP
,  	,  	 ,	O
correction  	correction  	 NN	O
of  	of  	 IN	O
underlying  	underlying  	 VBG	O
predisposing  	predisposing  	 JJ	O
factors 	factors 	 NNS	O
,  	,  	 ,	O
radical  	radical  	 JJ	B-NP
debridement  	debridement  	 NN	I-NP
of  	of  	 IN	O
affected  	affected  	 JJ	O
tissues 	tissues 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
extended  	extended  	 VBD	O
antifungal  	antifungal  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
article  	article  	 NN	O
discusses  	discusses  	 NN	O
strategies  	strategies  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
effective  	effective  	 JJ	O
management  	management  	 NN	O
of  	of  	 IN	O
invasive  	invasive  	 JJ	B-NP
mycoses 	mycoses 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
particular  	particular  	 JJ	O
focus  	focus  	 NN	O
on  	on  	 IN	O
antifungal  	antifungal  	 JJ	B-NP
hepatotoxicity 	hepatotoxicity 	 NN	I-NP
.  	.  	 .	O
